Barbara A. Hendrickson

2.7k total citations · 2 hit papers
47 papers, 2.0k citations indexed

About

Barbara A. Hendrickson is a scholar working on Immunology, Rheumatology and Epidemiology. According to data from OpenAlex, Barbara A. Hendrickson has authored 47 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 9 papers in Rheumatology and 7 papers in Epidemiology. Recurrent topics in Barbara A. Hendrickson's work include Rheumatoid Arthritis Research and Therapies (7 papers), Statistical Methods in Clinical Trials (6 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Barbara A. Hendrickson is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (7 papers), Statistical Methods in Clinical Trials (6 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Barbara A. Hendrickson collaborates with scholars based in United States, Japan and Germany. Barbara A. Hendrickson's co-authors include Ranjana Gokhale, Judy H. Cho, Edward E. Max, Mark W. Musch, Barry Ladizinski, Jonathan I. Silverberg, Alvina D. Chu, Eugene B. Chang, Kevin Winthrop and Yoshiya Tanaka and has published in prestigious journals such as The Lancet, The Journal of Experimental Medicine and The Journal of Immunology.

In The Last Decade

Barbara A. Hendrickson

44 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

2021 250 citations Kristian Reich, Henrique D. Teixeira et al. The Lancet profile →
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

2020 180 citations Barbara A. Hendrickson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Barbara A. Hendrickson United States	22	522	386	359	353	349	47	2.0k
Jeffrey M Weinberg United States	29	905 1.7×	335 0.9×	330 0.9×	213 0.6×	1.1k 3.0×	151	3.1k
O. Dereure France	31	481 0.9×	483 1.3×	445 1.2×	202 0.6×	928 2.7×	274	3.6k
Simon Milling United Kingdom	30	1.9k 3.6×	763 2.0×	365 1.0×	437 1.2×	277 0.8×	87	3.1k
Suranjith L. Seneviratne United Kingdom	27	724 1.4×	164 0.4×	145 0.4×	195 0.6×	705 2.0×	108	3.2k
Yuumi Nakamura Japan	19	772 1.5×	891 2.3×	240 0.7×	85 0.2×	155 0.4×	46	2.1k
Françoise Cottrez France	25	2.1k 3.9×	486 1.3×	142 0.4×	164 0.5×	404 1.2×	43	3.1k
Charles Lam Austria	21	1.2k 2.2×	584 1.5×	123 0.3×	214 0.6×	338 1.0×	57	3.2k
Jorge Ocampo‐Candiani Mexico	28	279 0.5×	318 0.8×	135 0.4×	167 0.5×	920 2.6×	239	3.0k
Ingileif Jónsdóttir Iceland	29	1.2k 2.4×	479 1.2×	158 0.4×	192 0.5×	1.2k 3.5×	80	2.9k
Rahul Mahajan India	23	434 0.8×	151 0.4×	128 0.4×	78 0.2×	363 1.0×	211	1.9k

Countries citing papers authored by Barbara A. Hendrickson

Since Specialization

Citations

This map shows the geographic impact of Barbara A. Hendrickson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara A. Hendrickson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara A. Hendrickson more than expected).

Fields of papers citing papers by Barbara A. Hendrickson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara A. Hendrickson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara A. Hendrickson. The network helps show where Barbara A. Hendrickson may publish in the future.

Co-authorship network of co-authors of Barbara A. Hendrickson

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara A. Hendrickson. A scholar is included among the top collaborators of Barbara A. Hendrickson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara A. Hendrickson. Barbara A. Hendrickson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ball, Greg, Mengchun Li, Barbara A. Hendrickson, et al.. (2024). Aggregate IND Safety Reporting for Smaller Companies and Programs. Therapeutic Innovation & Regulatory Science. 58(2). 368–379.

Hendrickson, Barbara A., et al.. (2023). Value and Implementation of the Aggregate Safety Assessment Plan. Pharmaceutical Medicine. 37(3). 171–181. 2 indexed citations

Guttman‐Yassky, Emma, Jacob P. Thyssen, Jonathan I. Silverberg, et al.. (2022). Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies. Journal of Allergy and Clinical Immunology. 151(1). 172–181. 43 indexed citations

Ball, Greg, Barbara A. Hendrickson, Robert Gordon, et al.. (2021). Interdisciplinary Safety Evaluation for Learning and Decision-Making. Therapeutic Innovation & Regulatory Science. 55(4). 705–716. 2 indexed citations

Reich, Kristian, Henrique D. Teixeira, Marjolein de Bruin‐Weller, et al.. (2021). Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 397(10290). 2169–2181. 250 indexed citations breakdown →

Ball, Greg, Barbara A. Hendrickson, J.R. Buchanan, et al.. (2020). Global Regulatory Landscape for Aggregate Safety Assessments: Recent Developments and Future Directions. Therapeutic Innovation & Regulatory Science. 54(2). 447–461. 6 indexed citations

Ball, Greg, Tjark Reblin, J.R. Buchanan, et al.. (2019). A Framework for Safety Evaluation Throughout the Product Development Life-Cycle. Therapeutic Innovation & Regulatory Science. 54(4). 821–830. 8 indexed citations

Ryan, Caitriona, Jeffrey M. Sobell, Craig L. Leonardi, et al.. (2018). Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis. American Journal of Clinical Dermatology. 19(3). 437–447. 28 indexed citations

Tripp, Catherine S., Carolyn A. Cuff, Andrew Campbell, et al.. (2017). RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study. Advances in Therapy. 34(6). 1364–1381. 30 indexed citations

10.

Abramson, Steven B., Mukundan Attur, M.A. Karsdal, et al.. (2017). Safety, tolerability, and pharmacodynamics of an anti-interleukin-1α/β dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study. Osteoarthritis and Cartilage. 25(12). 1952–1961. 61 indexed citations

11.

Beveridge, Mara, et al.. (2011). Local Vaccine Site Reactions and Contact Allergy to Aluminum. Pediatric Dermatology. 29(1). 68–72. 11 indexed citations

12.

Davids, Barbara J., Joy Palm, Michael P. Housley, et al.. (2006). Polymeric Immunoglobulin Receptor in Intestinal Immune Defense against the Lumen-Dwelling Protozoan Parasite Giardia. The Journal of Immunology. 177(9). 6281–6290. 66 indexed citations

13.

McNeal, Monica, Susan Stone, Mitali Basu, et al.. (2006). Protection against rotavirus shedding after intranasal immunization of mice with a chimeric VP6 protein does not require intestinal IgA. Virology. 346(2). 338–347. 31 indexed citations

14.

Kojima, Keishi, Mark W. Musch, Hongyu Ren, et al.. (2003). Enteric flora and lymphocyte-derived cytokines determine expression of heat shock proteins in mouse colonic epithelial cells. Gastroenterology. 124(5). 1395–1407. 93 indexed citations

15.

Musch, Mark W., et al.. (2001). Surgical stress shifts the intestinal Eschericia coli population to that of a more adherent phenotype: Role in barrier regulation. Surgery. 130(1). 65–73. 22 indexed citations

16.

Alverdy, John C., et al.. (1999). PERTURBED BIOELECTRICAL PROPERTIES OF THE MOUSE CECUM FOLLOWING HEPATECTOMY AND STARVATION. Shock. 12(3). 235–241. 11 indexed citations

17.

Hendrickson, Barbara A., David A. Conner, Daniel Ladd, et al.. (1995). Altered hepatic transport of immunoglobulin A in mice lacking the J chain.. The Journal of Experimental Medicine. 182(6). 1905–1911. 101 indexed citations

18.

Hendrickson, Barbara A.. (1979). Teachers Combat Burnout.. Learning Research and Practice. 7(5). 38–39. 2 indexed citations

19.

Hendrickson, Barbara A.. (1979). Teacher Burnout: How to Recognize It; What to Do about It.. Learning Research and Practice. 7(5). 37–39. 30 indexed citations

20.

Hendrickson, Barbara A.. (1979). Principals: Your Job Is a Hazard to Your Health.. The Executive educator. 1(3). 22–24. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact